Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
CASI Pharmaceuticals Inc (CASI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/08/2025: CASI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $4
1 Year Target Price $4
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 81.96% | Avg. Invested days 38 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 07/08/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 20.59M USD | Price to earnings Ratio - | 1Y Target Price 4 |
Price to earnings Ratio - | 1Y Target Price 4 | ||
Volume (30-day avg) 1 | Beta 0.63 | 52 Weeks Range 1.09 - 7.67 | Updated Date 07/8/2025 |
52 Weeks Range 1.09 - 7.67 | Updated Date 07/8/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.54 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -129.05% | Operating Margin (TTM) -163.99% |
Management Effectiveness
Return on Assets (TTM) -50.88% | Return on Equity (TTM) -1094.5% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 26382905 | Price to Sales(TTM) 0.66 |
Enterprise Value 26382905 | Price to Sales(TTM) 0.66 | ||
Enterprise Value to Revenue 0.84 | Enterprise Value to EBITDA 0.07 | Shares Outstanding 15492800 | Shares Floating 6146256 |
Shares Outstanding 15492800 | Shares Floating 6146256 | ||
Percent Insiders 43.76 | Percent Institutions 23.64 |
Upturn AI SWOT
CASI Pharmaceuticals Inc
Company Overview
History and Background
CASI Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics and pharmaceutical products in China and throughout the world. Founded to bridge the gap between Western and Chinese pharmaceutical markets, it has evolved into a global company. The company was founded in 1997.
Core Business Areas
- Commercial Operations: CASI focuses on commercializing approved pharmaceutical products in China, leveraging its regulatory expertise and distribution network.
- Drug Development: The company is engaged in the development of a pipeline of innovative drug candidates targeting hematology-oncology and other therapeutic areas.
Leadership and Structure
Wei-Wu He, Ph.D., is the Chairman and CEO. The company operates with a functional organizational structure, encompassing research and development, regulatory affairs, commercial operations, and finance.
Top Products and Market Share
Key Offerings
- EVOMELA: A proprietary intravenous formulation of melphalan used as a conditioning treatment prior to stem cell transplantation and for multiple myeloma. CASI holds commercial rights in China. Market share data not readily available. Competitors include generics of melphalan.
- CNCT-19 (CD19 CAR-T cell therapy): CASI holds rights to develop and commercialize CNCT-19 in Greater China. While approved CAR-T therapies like Yescarta and Kymriah exist, CNCT-19 targets a specific subset of leukemia patients. Competitors include Novartis (Kymriah) and Gilead (Yescarta).
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by intense competition, high R&D costs, and stringent regulatory requirements. The China market is experiencing rapid growth, driven by increasing healthcare spending and an aging population.
Positioning
CASI Pharmaceuticals aims to establish a strong presence in the Chinese pharmaceutical market by leveraging its strategic partnerships and innovative drug pipeline. It focuses on hematology-oncology.
Total Addressable Market (TAM)
The pharmaceutical market in China is substantial and growing. The TAM for hematology-oncology products is significant, driven by the increasing prevalence of cancer and related diseases. CASI is positioned to capture a portion of this TAM through its marketed products and development pipeline.
Upturn SWOT Analysis
Strengths
- Strong regulatory expertise in China
- Established commercial infrastructure in China
- Strategic partnerships with global pharmaceutical companies
- Innovative drug pipeline
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Dependence on partnerships for drug development
- Small commercial product portfolio
- Reliance on the Chinese market
Opportunities
- Expanding market access in China
- Acquiring or licensing additional pharmaceutical products
- Developing novel therapeutics for unmet medical needs
- Expanding into other Asian markets
Threats
- Intense competition from established pharmaceutical companies
- Pricing pressures from government regulations
- Regulatory changes in China
- Clinical trial failures
Competitors and Market Share
Key Competitors
- GILD
- NVS
- JNJ
- BMY
Competitive Landscape
CASI is a relatively small player in a highly competitive market dominated by large pharmaceutical companies. Its competitive advantages include its regulatory expertise in China and its partnerships with global pharmaceutical companies. Its disadvantages include its limited financial resources and small commercial product portfolio.
Major Acquisitions
No recent significant acquisition is avialable
- Year: 2024
- Acquisition Price (USD millions): 0
- Strategic Rationale: N/A
Growth Trajectory and Initiatives
Historical Growth: CASI's growth has been driven by the acquisition and commercialization of pharmaceutical products in China and development of their pipeline.
Future Projections: Future growth is dependent on the success of its drug pipeline and commercialization efforts. Consult analyst reports for specific revenue and earnings projections.
Recent Initiatives: Recent initiatives include expanding its commercial team in China, progressing its drug pipeline through clinical trials, and seeking new partnerships to expand its product portfolio.
Summary
CASI Pharmaceuticals operates in a challenging but promising market. Its strength lies in regulatory proficiency within China and strategic alliances. It needs to be mindful of its reliance on partnerships and smaller market share. Future success is linked to pipeline success and expanding commercial reach within Asia.
Peer Comparison
Sources and Disclaimers
Data Sources:
- CASI Pharmaceuticals Investor Relations
- SEC Filings
- Company Press Releases
- Third party pharmaceutical market research reports
Disclaimers:
This analysis is based on publicly available information and analyst estimates. It should not be considered financial advice. Market share estimates are approximate and may vary depending on the source.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About CASI Pharmaceuticals Inc
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 1996-06-11 | Chairman & CEO Dr. Wei-Wu He Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 233 | |
Full time employees 233 | |||
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation and as a palliative treatment for patients with multiple myeloma. The company's hematology/oncology assets in pipeline include CNCT19, an autologous CD19 CAR-T investigative product; BI-1206, an novel anti-Fc"RIIB antibody for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. It has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.